Business Wire

Comprehensive and Reliable Total Nucleic Acid Extraction from FFPE Samples with Covaris truXTRAC® FFPE SMART Solutions

17.4.2023 22:22:00 EEST | Business Wire | Press release

Share

Covaris, LLC, a leader in pre-analytical sample preparation technologies, proudly unveils a comprehensive, fully automatable deparaffinization and total nucleic acid extraction workflow for formalin-fixed paraffin-embedded (FFPE) samples. Covaris truXTRAC FFPE SMART Solutions are designed for use with Covaris’ high-throughput focused-ultrasonicators and include all reagents, consumables, and accessories used in the workflow that caters to a wide range of throughput requirements.

Combining truXTRAC FFPE SMART Solutions with Covaris’ class-leading Adaptive Focused Acoustics® (AFA®) technology offers laboratories working with FFPE tissues high-quality DNA and RNA recovery in a scalable, efficient workflow that can be partially or fully automated from deparaffinization through isolation and purification steps. ​All this can be achieved while addressing throughput requirements and providing reliable, robust, and reproducible results. Covaris truXTRAC FFPE SMART Solutions ensure extraction and purification of DNA as well as RNA, which is otherwise difficult to process from FFPE samples. Compared to traditional workflows for FFPE samples, truXTRAC FFPE SMART Solutions do not require use of any harmful organic solvents such as xylene or hexadecane. The customized accessories included in truXTRAC FFPE SMART Solutions allow each step within the workflow to be automated and are compatible with most automated liquid handlers and on-deck or deck-adjacent instruments, such as capper/decappers, centrifuges, and Covaris’ R230 or LE220 focused-ultrasonicators.

The high-throughput focused-ultrasonicators highlighted in the workflow feature Covaris’ patented AFA technology. Using active, non-contact, mechanical deparaffinization, this technology enables complete and efficient deparaffinization without the use of harsh chemicals, resulting in recovery of high-quality DNA and RNA, while maintaining data reliability and reproducibility.

“FFPE samples contain critical information about a person’s health and hence are investigated in an array of application types,” said Annemarie Watson, CEO of Covaris, LLC. “Covaris’ truXTRAC FFPE SMART Solutions ensure high quality and yield of DNA and RNA while addressing a wide range of throughput requirements. These advantages enable researchers to generate confident, meaningful results that have impact in medical and scientific communities.”

About Covaris

Based in Woburn, MA, Covaris develops, manufactures, and markets instruments, consumables, and reagents used in pre-analytical sample preparation for genomic and proteomic analysis to help accelerate the pace of research and life science innovations. Using proprietary technologies including focused acoustic energy, Covaris’ tools achieve highly accurate and reproducible results with the goal of empowering customers to make new discoveries, develop new assays and improve bioanalytical results. Some of the non-contact applications include faster automated DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension, and compound formulation.

Additional information about Covaris, LLC is available at www.covaris.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kate Meola
Covaris, Inc.
+1 781-932-3959
kmeola@covaris.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye